Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (Weighted Average) (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $16667.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) fell 80.44% year-over-year to $16667.0, compared with a TTM value of $16667.0 through Dec 2025, down 80.44%, and an annual FY2025 reading of $16667.0, down 80.44% over the prior year.
  • Shares Outstanding (Weighted Average) was $16667.0 for Q4 2025 at Spyre Therapeutics, roughly flat from $16667.0 in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $82.2 million in Q2 2022 and bottomed at $8630.0 in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $29.3 million, with a median of $4.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 1184.59% in 2024, then tumbled 99.97% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $2.6 million in 2021, then grew by 22.56% to $3.2 million in 2022, then crashed by 99.73% to $8630.0 in 2023, then skyrocketed by 887.35% to $85208.0 in 2024, then tumbled by 80.44% to $16667.0 in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SYRE at $16667.0 in Q4 2025, $16667.0 in Q3 2025, and $346045.0 in Q2 2025.